Review of European bio companies that will make achievements in 2018

Market analysis of China Pharmaceutical network 】In 2017, as a year of mixed happiness and sorrow in the biotechnology industry, more and more investors chose to withdraw from the biotechnology market However, the FDA of the United States has approved 46 new drugs, and also approved car-t, a cell therapy with great innovative significance, and a gene therapy drug for rare eye diseases Although the industry is still discussing the pricing of drugs No, but it doesn't seem to change, because the prices of these drugs are very high At the same time, in terms of M & A, 2017 is not an impressive year (except for J & J's $30 billion acquisition of actelion) Forget the good and bad of 2017 The new 2018 has come Here is a summary of European bio companies that will make some achievements in the industry through their own efforts in 2018: 1 Jean Paul, founder of idorsia actelion Clozel and his wife, Martine, started a new attempt after selling actelion Idorsia, a Swiss pharmaceutical company independent of actelion's drug discovery and early clinical development business, released the results of active phase 2 clinical trials on new drugs for insomnia last summer The company decided to make this important drug enter phase 3 clinical trials as soon as possible Experiment The company has signed an immunotherapy cooperation agreement with Roche and an option agreement with actelion's purchaser, Johnson & Johnson pharmaceutical In 2018, we need to continue to focus on the possibilities of idorsia and its powerful product pipeline 2 Ablynx ablynx2002 was founded This year, it is finally ready to put drugs on the market The nano antibody drug of the Belgian biological company, which is based on Alpaca antibody, has proved to be effective for the fatal autoimmune hematopathy The result was announced less than two days before the NASDAQ IPO of the company, and the company still performs well without partners According to Edwin Moses, the company plans to launch its attP drug in Germany in the third quarter of this year and is expected to enter the U.S market in early 2019 3 GW Pharma GW Pharma is a company familiar to practitioners outside the biotechnology industry The company is committed to developing and commercializing new therapies for its proprietary cannabinoid product platform Its stock performance last year was also outstanding If the FDA's approval goes well, epidilex could join the blockbuster drug club this year with its launch 4 In the face of the increasingly serious antibiotic crisis, motifbio may have a new product added to the antibiotic treatment army in 2018 In the fall of last year, iclaprim released the results of a positive phase 3 clinical trial, and the company plans to first file an application for listing in the United States at the beginning of this year The company has received £ 17 million in financing from Hercules capital 5 Gensight gensight published the results of gene therapy gs010 for a rare hereditary optic neuropathy last year The patients have a long-term vision recovery, which provides a very effective treatment path for these patients The treatment is currently in clinical phase 3 and some results are expected this year If it works, it could be one of the first gene therapies, after the FDA approved Spark's gene therapy for rare eye diseases 6 Nightstarx, a derivative company of Oxford University in the UK, has also made waves in gene therapy of rare eye diseases Last year, the company raised 40 million euros in round C financing before raising 75 million dollars (64 million euros) on NASDAQ All funding will be used to advance the company's key phase 3 trials of key candidate drugs for choroideremia treatment, which are expected to begin in the first half of this year 7 Gamma delta therapeutics is adopting a new method to study T cells The new T cell technology platform is based on the diversity of human tissue γ δ T cells, which may have potential application value in allogeneic cell therapy Since the company raised seed money from companies like abingworth in September 2016 and recruited Paolo Paoletti, a senior oncologist, to lead the company in May last year, gamma delta has signed an important partnership with Takeda to develop its technology for the treatment of cancer and self-inflammatory diseases Although the company is still in the early stages of scientific and commercial development, we are looking forward to seeing the development direction of gamma delta this year 8 Kymab has raised 220 million US dollars (190 million euros) so far, and no candidate drug has been put into clinical practice As David chiswell, the executive, put it, the company has chosen "a very difficult path, and it will cost a lot." Kymouth, a candidate drug based on the company's mouse antibody discovery platform, entered the clinic last year and is expected to obtain data in 2019 After the first half of this year, we will pay close attention to the release of any interim data 9 DNA script, a French company, successfully attracted the attention of Illumina ventures last year as a leading investor in the 11 million euro round a financing The company's goal is to go all out to promote the revolutionary innovation of DNA synthesis technology, completely change DNA synthesis, and prepare for the scale of industrialization next year Thomas ybert, executive and co-founder, sees DNA as the next silicon element and hopes to be available in the DNA synthesis market Original title: 9 biological companies worthy of attention in Europe in 2018